𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide

✍ Scribed by Youngil Koh; Soo-Mee Bang; Jae Hoon Lee; Hwi-Joong Yoon; Young-Rok Do; Hun-Mo Ryoo; Nari Lee; Seok Jin Kim; Kihyun Kim; Sung-Soo Yoon; Jong-Ho Won; Yeung-Chul Mun; Moon-Hee Lee; Ki-Hyun Rhee; Hyo-Jung Kim; HyeonSeok Eom; Min Kyoung Kim; Hyun Chun Shin; Korean Multiple Myeloma Working Party

Publisher
Springer
Year
2009
Tongue
English
Weight
123 KB
Volume
89
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Prophylactic recombinant erythropoietin
Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis
✍ Elias J. Anaissie; Elizabeth A. Coleman; Julia A. Goodwin; Robert L. Kennedy; Ki πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 186 KB πŸ‘ 1 views

## Abstract ## BACKGROUND: Venous thromboembolism (VTE) is a significant but poorly understood complication in patients with newly diagnosed multiple myeloma (NDMM). As a result, most patients receive thromboprophylaxis with low molecular weight heparin (LMWH). The purpose of this retrospective st

The clinical impact and molecular biolog
The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy
✍ Kevin D. Boyd; Fiona M. Ross; William J. Tapper; Laura Chiecchio; GianPaolo Dagr πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 205 KB πŸ‘ 1 views

## Abstract Hemizygous deletion of 17p (del(17p)) has been identified as a variable associated with poor prognosis in myeloma, although its impact in the context of thalidomide therapy is not well described. The clinical outcome of 85 myeloma patients with del(17p) treated in a clinical trial incor

P140 Prognostic impact of 1q21 amplifica
P140 Prognostic impact of 1q21 amplification in patients with multiple myeloma treated by velcade, thalidomide and any conventional chemotherapy
✍ P. Nemec; P. Kuglik; V. Vranova; R. Zaoralova; H. Greslikova; A. Oltova; H. Filk πŸ“‚ Article πŸ“… 2007 πŸ› Elsevier Science 🌐 English βš– 47 KB

Conclusions: Among their pts with GI nHl the slow increase of incidence from all lymphoma cases, the slight decrease of MALT lymphomas, the elevation of cases of intestinal and of gastric lymphomas with high grade B-cell origin and at all, in this latter group the beneficial effect of rituximab+CHOP